Navigation Links
Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
Date:9/21/2010

RYE, N.Y., Sept. 21 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Rodman & Renshaw Annual Global Investment Conference held September 12-15 in New York City.  The global investment conference attracted more than 5,000 investors and other attendees.  

"Curemark was one of only a handful of private companies invited to present at the conference, which included a full roster of 610 companies presenting," said Dr. Joan Fallon said, Curemark founder and CEO.  "To be able to participate was a terrific opportunity to showcase our progress, as the event was essentially a packed house."

At the conference, Fallon discussed the momentum of Curemark's drug pipeline.  CM-AT, the company's autism treatment in development, is currently in Phase III clinical trials at 13 sites nationwide and has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).  The FDA also has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of the company's compound CM-4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

Curemark's autism treatment targets enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/7/2020)... ... April 07, 2020 , ... West Boca Eye Center ... Coronavirus pandemic means health care providers are adopting radical precautions while treating patients. In ... procedures except those of an urgent or emergency nature. Brent Bellotte MD. explains how ...
(Date:4/5/2020)... ... April 04, 2020 , ... As the ... for medical supplies, diagnostics, and treatments. Shortages of such supplies are plaguing hospitals ... , Tran & Associates supports the fight against COVID-19 and encourages every-day ...
(Date:4/2/2020)... ... April 02, 2020 , ... ... introduces the KRT Series, a portable, durable luminaire using Indigo-Clean Technology. These unique ... bolstering existing cleaning and infection prevention protocols, and reducing harmful bacteria when used ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... April 02, 2020 , ... The Northern Virginia Community College ... from donor Debra Coffman Howe of Palm Beach, Florida. Ms. Howe is adding ... Supporting NOVA nursing is more important than ever given the current pandemic. Ms. ...
(Date:4/1/2020)... ... 2020 , ... AAGL Gynecologic Surgeons host a global webinar ... safety practices in response to the COVID-19 crisis. , AAGL frontline surgeons ... Orleans and Amsterdam University Medical Center in the Netherlands will discuss what every ...
(Date:4/1/2020)... , ... April 01, 2020 , ... ... (PPE) to stay safe while treating Coronavirus-infected patients. , Staffers are in particular ... can transmit coronavirus. Earlier this week, The Wall Street Journal reported that New ...
(Date:4/1/2020)... ... April 01, 2020 , ... ... information under California law,” says Keller Grover LLP attorney Eric A. Grover. ... data breaches and the negligent release and disclosure of medical information can, under ...
(Date:3/28/2020)... (PRWEB) , ... March 27, 2020 , ... ... division of the Suntuity Group of companies, is mobilizing their drone equipment and ... coronavirus. , By leveraging their DJI Enterprise level Matrice and Agras drones, Suntuity ...
Breaking Medicine News(10 mins):